Montelukast (Singulair) Warning – FDA

The U.S. Food and Drug Administration (FDA) announced that it is requiring a boxed warning for montelukast (Singulair) due to the risk of neuropsychiatric events, such as agitation, depression, sleeping problems and suicidal thought and actions. The actual incidence of neuropsychiatric events associated with montelukast is unknown. As with any drug, the risks vs the benefits should be weighed...
read more